Lakewood-Amedex Biotherapeutics, Inc.
Explore Lakewood-Amedex Biotherapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Pros
No pros available.
Cons
No cons available.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vertex Pharmaceuticals Incorporated | $451.63 | 26.79 | $114.63 B | — | — | 0.24% | $507.92 / $362.5 | $76.18 |
| 2. | Regeneron Pharmaceuticals, Inc. | $676.23 | 15.66 | $69.27 B | 0.56% | 10.23% | 14.32% | $821.11 / $532.6 | $295.71 |
| 3. | Alnylam Pharmaceuticals, Inc. | $321.59 | 73.48 | $42.41 B | — | 14.33% | 98.29% | $495.55 / $273.11 | $5.96 |
| 4. | Revolution Medicines, Inc. | $190.46 | — | $40.7 B | — | -57.28% | -54.06% | $193.69 / $34 | $8.28 |
| 5. | Roivant Sciences Ltd. | $36.31 | — | $34.93 B | — | -21.06% | -6.85% | $36.49 / $10.71 | $6.28 |
| 6. | Royalty Pharma plc | $57.8 | 40.22 | $33.27 B | 1.63% | 8.21% | 12.67% | $58.17 / $34.08 | $11.22 |
| 7. | Moderna, Inc. | $79.77 | — | $31.62 B | — | -29.7% | -36.73% | $85.6 / $22.28 | $21.95 |
Quarterly Results
Figures shown in M / B
| Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -0.89 M | -0.71 M | -1.88 M | -0.54 M | -0.86 M | — |
| Net Profit | -0.92 M | -0.74 M | -1.91 M | -0.54 M | -0.85 M | — |
| EPS in Rs | -0.2 | — | -0.14 | -0.15 | — | -0.28 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Sales | 0 M | 0 M | 0 M |
| Operating Profit | -3.77 M | -4.03 M | -8.64 M |
| Net Profit | -3.85 M | -4.86 M | -8.28 M |
| EPS in Rs | -0.28 | -0.69 | -1.18 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Total Assets | 0.48 M | 1.07 M | 6.89 M |
| Total Liabilities | 2.45 M | 0.66 M | 2.34 M |
| Equity | -1.96 M | 0.41 M | 4.56 M |
| Current Assets | 0.31 M | 0.77 M | 6.48 M |
| Current Liabilities | 2.41 M | 0.5 M | 2.06 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating CF | -1.94 M | -5.72 M | -6.82 M |
| Investing CF | 0 M | 3.92 M | -3.78 M |
| Financing CF | 1.5 M | -0.05 M | 0 M |
| Free CF | -1.94 M | -5.73 M | -6.82 M |
| Capex | — | -0 M | — |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue Growth % | — | — | — |
| Earnings Growth % | 20.76% | 41.37% | — |
| Profit Margin % | — | — | — |
| Operating Margin % | — | — | — |
| Gross Margin % | — | — | — |
| EBITDA Margin % | — | — | — |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
No dividend history available.
Stock Splits
No stock split history available.
Frequently Asked Questions — Lakewood-Amedex Biotherapeutics, Inc.
Will Lakewood-Amedex Biotherapeutics, Inc. stock hit $0 in 2026?
Lakewood-Amedex Biotherapeutics, Inc. (LABT) is currently trading at $0.39, with a 52-week range of $0.37 to $9.82. Reaching the $0 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.
Whether Lakewood-Amedex Biotherapeutics, Inc. can reach $0 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.
Short-term price predictions carry significant uncertainty — stock prices can be influenced by factors ranging from quarterly earnings surprises to global macroeconomic events. Use the LABT Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.
Is Lakewood-Amedex Biotherapeutics, Inc. stock worth buying at $0.39?
Whether Lakewood-Amedex Biotherapeutics, Inc. (LABT) is worth buying at $0.39 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:
Valuation: Valuation data is currently limited — check the full ratios section on StockSifting for the latest P/E, P/B, and EV/EBITDA figures.
Profitability & efficiency:
Financial health: Review the balance sheet section on StockSifting for the latest debt levels, cash reserves, and liquidity ratios.
Analyst view: Analyst estimates are not currently available for LABT. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.
What is the analyst price target for Lakewood-Amedex Biotherapeutics, Inc. (LABT) in 2026?
Analyst price target data for Lakewood-Amedex Biotherapeutics, Inc. (LABT) is not currently available on StockSifting. Analyst coverage and price targets are typically published by brokerage research desks for widely followed stocks, and are updated regularly after earnings results or major corporate events. Check back for the latest estimates, or explore LABT's financial ratios, historical returns, and fundamental data available on this page to form your own view.
What will Lakewood-Amedex Biotherapeutics, Inc. stock be worth in 2029?
Projecting Lakewood-Amedex Biotherapeutics, Inc. (LABT)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.
In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.
You can model different scenarios — conservative, base, and bull case — using the LABT Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.